Alydia Health
→
Organon (via Merck spinoff)
Acquisition · Cash · OGN · announced Mar 30, 2021
Announced
Mar 30, 2021
Closed
Jul 1, 2021
Economics
Cash
Up to $240M total ($215M upfront cash + $25M contingent milestone); Organon press release Mar 30, 2021
Target
Alydia Health
Maternal Health · Clinical / therapeutic
HQ Menlo Park, CA · Founded 2011
Medical device company focused on preventing maternal morbidity from postpartum hemorrhage (Jada System)
- Organon.com - press release (Mar 30, 2021)
- Business Wire - Merck acquisition on behalf of Organon spinoff
- Crunchbase - crunchbase.com/organization/alydia-health
Acquirer
Organon (OGN)
Reproductive Health
HQ Jersey City, NJ
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Jada System addresses postpartum hemorrhage — aligns with Organon's mission as global women's health leader; potential EU/global expansion
Evidence ladder
Secondary (press / IR)
Organon.com press release (Mar 30, 2021)
Secondary (press / IR)
Business Wire
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/1821825/000119312521180652/d49288dex992.htm
Open source
Limitations
- Up to $240M total ($215M upfront cash + $25M contingent milestone); Organon press release Mar 30, 2021
Valuation peers · Maternal Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Insufficient disclosed data
No verified Maternal Health deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.
Other verified deals by Organon
Acquirer program history not already listed as a valuation peer or adjacency row.
| Sector | ||||
|---|---|---|---|---|
| Dermavant Sciences | Organon | Sep 18, 2024 | Dermatology | |
| Forendo Pharma | Organon | Nov 11, 2021 | Reproductive Health |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Alydia Health (Maternal Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 3 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.